Enanta Pharmaceuticals Inc (ENTA)vsMerck & Company Inc (MRK)
ENTA
Enanta Pharmaceuticals Inc
$12.96
+2.05%
HEALTHCARE · Cap: $388.24M
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 101909% more annual revenue ($66.57B vs $65.26M). MRK leads profitability with a 4.8% profit margin vs -96.9%. MRK earns a higher WallStSmart Score of 36/100 (F).
ENTA
Avoid21
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+36.6%
Fair Value
$22.49
Current Price
$12.96
$9.53 discount
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -53.2% — below average capital efficiency
Revenue declined 21.6%
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ENTA
ENTA has a balanced fundamental profile.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : ENTA
The primary concerns for ENTA are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
ENTA profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
ENTA carries more volatility with a beta of 0.93 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 21/100). ENTA offers better value entry with a 36.6% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Enanta Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?